Treating to intensive glycemic targets (glycosylated hemoglobin [A 1c]< 7%) increases the
risk of adverse events and is unlikely to provide benefit given the reduced life expectancy of …

(1) Background: The latest recommendations for diabetes management adapt the objectives
of glycemic control to the frailty profile in older patients. The purpose of this study was to …

OBJECTIVES: To determine the hypo‐and hyperglycemic outcomes associated with
implementing the American Geriatrics Society (AGS) guideline for a glycosylated …

Prognosis and appropriate treatment goals for older adults with diabetes vary greatly
according to frailty. It is now recognised that changes may be needed to diabetes …

Older adults with diabetes who are otherwise healthy and who have considerable life
expectancy (more than 10 years) should generally receive diabetes care with goals and …

Clinical practice guidelines specific to the medical care of frail older adults have yet to be
widely disseminated. Because of the complex conditions associated with frailty, guidelines …

The prevalence and incidence of type 2 diabetes mellitus (DM) increase with age, and its
diagnosis and treatment in older people present a challenge. Applying evidence to elderly …

Diabetes management should be individualized. 1 Newer antihyperglycemic agents (Table
1) such as glucagonlike peptide-1 receptor agonists (GLP1-RAs), dipeptidyl peptidase 4 …

Understanding the benefits and risks of treatments to be used by older individuals (≥ 65
years old) is critical for informed therapeutic decisions. Glucose‐lowering therapy for older …

With increasing age, frailty is recognized as an emerging new diabetes-related complication
[1]. As life expectancy is increasing, the number of older people with comorbid diabetes and …